Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 14, 2016. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on October 13, 2016, on the London Stock Exchange (XLON).
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Dividend Re-investment | Ordinary Shares (25p each) | 17.038876 | 9,263 |
Note: Total volume is the aggregate of individual transactions listed below.
Material Changes and Transaction Details
The filing reports the following acquisitions of ordinary shares following the re-investment of dividends paid on October 13, 2016:
- Sir Andrew Witty (CEO): 6,771 shares
- Lady C Witty (PCA of CEO): 1,897 shares
- Mr J P Witty (PCA of CEO): 55 shares
- Ms S Witty (PCA of CEO): 56 shares
- Mrs V A Whyte (Company Secretary): 86 shares
- Mr I W Whyte (PCA of Company Secretary): 371 shares
- Mrs D Connor (PCA of President, Global Manufacturing & Supply): 217 shares
All transactions were executed at a uniform price of GBP 17.038876 per share.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the dividend payment date of October 13, 2016, to confirm the timing of the re-investment.
- Confirm the market price of GSK ordinary shares on the London Stock Exchange on October 13, 2016, against the reported transaction price of GBP 17.038876.
- Review the total shareholding positions of the named PDMRs and PCAs post-transaction to assess concentration of ownership.
- Note that this filing contains no operational or financial performance data for the company.